VESTAMID® Terra Featured At 2012 Bioplastics Compounding And Processing Conference

PARSIPPANY, N.J., May 8, 2012

Evonik’s VESTAMID® Terra VESTAMID® Terra, a polyamide product line made from biogenic renewable raw materials, will be featured at the Bioplastics Compounding and Processing Conference Bioplastics Compounding and Processing Conference in Miami, Fla., on May 8-9, 2012.

“VESTAMID® Terra polyamides fulfill the demanding technical requirements in a variety of applications including injection molding, extrusion, fibers and filaments, and are a perfect solution to the rising demand for resource-efficient products,” said Douglas Weishaar, business development manager of Evonik’s High Performance Polymers business unit. “When ingredients from plants are converted into chemical raw materials, carbon dioxide is produced in significantly lower volumes than when fossil raw materials are used.”

The monomers found in VESTAMID® Terra are derived from castor bean oil and cultivation doesn’t affect food production nor cause land-use change, creating a more efficient carbon dioxide balance and making biobased polyamides an alternative to polyamides derived from petroleum.

VESTAMID® Terra is available in pellet form as a base polymer and comes in three grades: VESTAMID® Terra DD, VESTAMID® Terra HS and VESTAMID® Terra DS, which are based up to 45 percent, 62 percent and 100 percent on natural resources, respectively.

VESTAMID® Terra’s technical properties are comparable to polyamide 12’s (PA 12)’s and have similar process requirements. Additionally, VESTAMID® Terra does not require cyclododecatriene (CDT) as a precursor and is today being used in key automotive industry applications such as hydraulic clutch lines.

For additional information about Evonik in North America, please visit our website: www.evonik.com/north-america.

Downloads

Contact

Dan Yampolsky

Contact

  • About Evonik

    Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Evonik benefits specifically from its innovative prowess and integrated technology platforms.

    Evonik is active in over 100 countries around the world. In fiscal 2011 more than 33,000 employees generated sales of around €14.5 billion and an operating profit (EBITDA) of about €2.8 billion.

  • Disclaimer

    In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.